Massimo Iacobelli
Overview
Explore the profile of Massimo Iacobelli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
1034
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bonomini M, Davies S, Kleophas W, Lambie M, Reboldi G, Di Liberato L, et al.
Perit Dial Int
. 2024 Aug;
45(1):17-25.
PMID: 39205396
Peritoneal dialysis adoption and technique survival is affected by limitations related to peritoneal membrane longevity and metabolic alterations. Indeed, almost all peritoneal dialysis fluids exploit glucose as an osmotic agent...
2.
Gronda E, Gallieni M, Pacileo G, Capasso G, Wei L, Trepiccione F, et al.
Kidney Blood Press Res
. 2024 Aug;
49(1):852-862.
PMID: 39197425
Introduction: Peritoneal ultrafiltration (PUF) has been proposed as an additional therapeutic option for refractory congestive heart failure (RCHF) patients. Despite promising observational studies and/or case report results, limited clinical trial...
3.
Mo C, Richardson E, Calabretta E, Corrado F, Kocoglu M, Baron R, et al.
Blood Rev
. 2024 Jun;
66:101218.
PMID: 38852017
Patients with multiple myeloma (MM) were among the groups impacted more severely by the COVID-19 pandemic, with higher rates of severe disease and COVID-19-related mortality. MM and COVID-19, plus post-acute...
4.
Ruggeri A, Corrado F, Voza A, Wei L, Catalano G, Liberatore C, et al.
Haematologica
. 2024 May;
109(10):3261-3268.
PMID: 38779740
The coronavirus disease 2019 (COVID-19) pandemic led to an unprecedented burden on healthcare systems around the world and a severe global socioeconomic crisis, with more than 750 million confirmed cases...
5.
Garcia-Bernal D, Richardson E, Vlodavsky I, Carlo-Stella C, Iacobelli M, Jara R, et al.
EJHaem
. 2021 Sep;
2(3):680-681.
PMID: 34518829
No abstract available.
6.
Lademann J, Mansouri P, Nahavandi A, Ahlers A, Zibakalam-Mofrad F, Brower B, et al.
Skin Pharmacol Physiol
. 2021 Aug;
34(6):337-350.
PMID: 34404045
Background: The chronicity of psoriasis often requires continuous topical treatment. Materials And Methods: Here, the radical protection of a cream containing various herbal oils was evaluated in vivo by electron...
7.
Richardson E, Garcia-Bernal D, Calabretta E, Jara R, Palomo M, Baron R, et al.
Expert Opin Ther Targets
. 2021 Jun;
25(6):423-433.
PMID: 34167431
Introduction: Defibrotide (DF) is a polyribonucleotide with antithrombotic, pro-fibrinolytic, and anti-inflammatory effects on endothelium. These effects and the established safety of DF present DF as a strong candidate to treat...
8.
Calabretta E, Moraleda J, Iacobelli M, Jara R, Vlodavsky I, OGorman P, et al.
Br J Haematol
. 2021 Feb;
193(1):43-51.
PMID: 33538335
No abstract available.
9.
Richardson E, Carlo-Stella C, Jara R, Vlodavsky I, Iacobelli M, Fareed J, et al.
J Thromb Haemost
. 2020 Aug;
18(11):3111-3113.
PMID: 32860297
No abstract available.
10.
Tappe W, Aggarwal S, Topaloglu O, Iacobelli M
Clin Appl Thromb Hemost
. 2020 Jul;
26:1076029620935202.
PMID: 32687402
Defibrotide is approved to treat hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) with renal/pulmonary dysfunction following hematopoietic cell transplantation (HCT) in adult and pediatric patients in the United States, and to...